Clinician POV

Clinician POV

Distinguishing HER2-Negative From HER2-Low Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, is a professor of medicine at the University of Pittsburgh School of Medicine in Pennsylvania and the associate division chief of the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine. Dr Brufsky is the medical director of the Magee-Womens Cancer Program, associate director for clinical investigations, and codirector of the Comprehensive Breast Cancer Center at UPMC Hillman Cancer Center.
Roger Li, MD

Identifying Actionable Genetic Alterations in Metastatic Urothelial Carcinoma

Roger Li, MD, is a genitourinary oncologist at Moffitt Cancer Center, in Tampa, Florida. His clinical focus includes surgical treatment of bladder, prostate, kidney, and penile cancer. His research interests include genomic characterization of genitourinary malignancies to tailor therapy to the individual patient and development of novel immunotherapeutic strategies for early-stage bladder cancer.

Therapeutic Options for Nonmetastatic Castration-Resistant Prostate Cancer

Jingsong Zhang, MD, PhD, is a genitourinary oncologist and interim vice chair of the Department of Genitourinary Oncology at Moffitt Cancer Center, Tampa, Florida. Dr Zhang’s work has been published in multiple medical journals. He is board certified in medical oncology and internal medicine, and his primary interest is in developing new treatments for prostate cancer.

Achieving Testosterone Suppression in Advanced Prostate Cancer

Neal Shore, MD, FACS, is the medical director of the Carolina Urologic Research Center, Myrtle Beach, South Carolina. He practices with Atlantic Urology Clinics in Myrtle Beach. Dr Shore is an internationally recognized expert in systemic therapy for advanced urologic cancers and has conducted more than 250 clinical trials.  READ MORE »